Kotobuki’s History

dozo1

1949
Establishment of Kotobuki Pharmaceutical
Started to sell herbal medicines which are extracted from herbs that are mainly produced in Nagano Prefecture
1965
Start to develop of synthetic active pharmaceutical ingredients focused particularly on research on manufacturing imported active pharmaceutical ingredients domestically
1969
Launched Gastritis, Gastric ulcer, duodenal ulcer therapeutic agent MARZULENE-S GRANULES in Japan
1978
Completion of pharmacy plant based on GMP (Good Manufacturing Practice)
Completion of the first stage construction of Research Laboratory
麦滋林(中国)
麦滋林(china)
GLUTAZENE(India)
AZULOXA GRANULES(South Korea)
AZULOXA GRANULES(South Korea)
Suglat Tablets 25mg、50mg
Suglat Tablets 25mg、50mg
1987
Completion of the second stage construction of Research Laboratory
This leads to a start of full-scale development of new pharmaceuticals
1989
Completion of research facilities of Radio Isotope
1990
Launched Gastritis, Gastric ulcer, duodenal ulcer therapeutic agent MARZULENE-S GRANULES in China
1993
Completion of the second pharmacy plant based on GMP
2000
Launched Gastritis, Gastric ulcer, duodenal ulcer therapeutic agent MARZULENE-S GRANULES in India
2001
Launched new Gastric ulcer therapeutic agent AZULOXA GRANULES (Egualen Sodium) in Japan
2003
Launched Gastritis, Gastric ulcer, duodenal ulcer therapeutic agent MARZULEN ES TABLETS (Dosage form addition)
2004
Launched Gastric ulcer therapeutic agent AZULOXA GRANULES in South Korea
Conformed to the inspection for compliance with the GCP (Good Clinical Practice)carried out by PMDA (Pharmaceuticals and Medical Devices Agency)
2005
Conformed to the inspection on synthesized drug substances carried out by foreign country regulatory authority
2006
Conformed to the inspection on AZULOXA GRANULES for compliance with the GPMSP (Good Post-Marketing Surveillance Practice) carried out by PMDA
2008
Launched Gastritis, Gastric ulcer, duodenal ulcer therapeutic agent MARZULEN COMBINATION TABLETS 0.5ES (Dosage form addition)
2009
Launched Gastritis, Gastric ulcer, duodenal ulcer therapeutic agent MARZULEN COMBINATION TABLETS 0.375ES (Dosage form addition)
2010
We performed an invitation lecture of KT6-971 by a medicinal chemistry sectional meeting of Americanization society(ACS)
2011
Gastric ulcer therapeutic agent AZULOXA TABLETS 15mg in Japan
2012
We changed development number of cholesterol absorption inhibitor KT6-971 to S-556971.
2013

Submits Application for Marketing Approval of Ipragliflozin /S Suglat Tablets 25mg、50mg

GLT2 Inhibitor for Treatment of Type 2 Diabetes(Joint development with Astellas Pharma Inc.), in Japan.

2014

Approval of Suglat Tablets, a Selective SGLT2 Inhibitor for Treatment of Type 2 Diabetes(Joint development with Astellas Pharma Inc.), acquires production sale approval in the country and is published medicine charge. It released it.

2015110509sakurasakura本社屋上から観た北アルプス